GE Healthcare Technologies operates with a distinctive valuation profile among large-cap medical technology providers, trading at a price-to-earnings ratio of 16.66x while delivering an 18.75% return on equity. The company's current price of $68.02 represents a 24.2% discount from its 52-week high of $89.77, occurring alongside a -12.27% year-over-year decline in earnings per share to $4.17. This compression creates a research perspective for systematic screening models focused on enterprise healthcare infrastructure exposure.

The fundamental profile reveals several notable characteristics:

• Profitability execution: Operating margin of 12.63% and net margin of 9.1% demonstrate operational discipline in the capital-intensive medical equipment sector, supported by a 39.14% gross margin that provides cushion for R&D investment and service operations.
• Return metrics: ROE of 18.75% exceeds typical industry benchmarks, while ROA of 5.25% reflects the asset-heavy nature of manufacturing and service infrastructure for imaging systems and diagnostics platforms.
• Balance sheet positioning: Debt-to-equity ratio of 0.97 and current ratio of 1.37 signal manageable leverage for a company separated from General Electric's legacy obligations in 2023, maintaining adequate working capital for operational needs.

Risk factors include the recent EPS contraction and moderating revenue growth of 5.97% year-over-year, potentially reflecting healthcare capital equipment cycle dynamics. The beta of 0.79 indicates lower volatility relative to broader markets. Against peers including Boston Scientific (BSX), Edwards Lifesciences (EW), and Becton Dickinson (BDX), GEHC's 1.52x price-to-sales ratio positions the stock at the lower end of medical technology valuations, with its $30.7 billion market capitalization reflecting diagnostic and imaging market leadership.